KBC Group
RVMD icon

KBC Group’s Revolution Medicines RVMD Stock Holding History

KBC Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
15,395
+11,196
+267% +$1.13M ﹤0.01% 696
2025
Q4 		$334K Hold
4,199
– – ﹤0.01% 774
2025
Q3 		$196K Hold
4,199
– – ﹤0.01% 913
2025
Q2 		$154K Sell
4,199
-1,932
-32% -$74.2K ﹤0.01% 975
2025
Q1 		$217K Buy
6,131
+1,152
+23% +$46.8K ﹤0.01% 1025
2024
Q4 		$218K Buy
4,979
+1,758
+55% +$88.7K ﹤0.01% 1081
2024
Q3 		$146K Buy
3,221
+368
+13% +$16K ﹤0.01% 1067
2024
Q2 		$111K Buy
2,853
+592
+26% +$22.1K ﹤0.01% 1110
2024
Q1 		$73K Hold
2,261
– – ﹤0.01% 1308
2023
Q4 		$65K Buy
2,261
+1,034
+84% +$24.8K ﹤0.01% 1346
2023
Q3 		$34K Buy
+1,227
New +$36.4K ﹤0.01% 1731

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KBC Group's RVMD Position: Q1 2026 in Review

KBC Group increased its Revolution Medicines (RVMD) stake by 267% in Q1 2026, buying an estimated $1.13M and bringing the position to 15,395 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #696.

KBC Group first reported a position in RVMD in Q3 2023 and has held it in 11 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • KBC Group held 15,395 shares of Revolution Medicines worth $1.5M as of Q1 2026.
  • KBC Group bought 11,196 Revolution Medicines shares in Q1 2026, an estimated $1.13M.
  • Revolution Medicines made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #696 holding.
  • KBC Group first reported a position in Revolution Medicines in Q3 2023 and has held it in 11 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.